Water extracts of immature Rubus coreanus regulate lipid metabolism in liver cells

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 1907-1913

  Bhandary, Bidur ^a   Lee, Geum Hwa ^b   Marahatta, Anu ^a   Lee, Hak Yong ^a   Kim, Sun Young ^c   So, Byung Ok ^c   Kwon, Ji Wung ^d   Song, Ji Young ^d   Lee, Hee Kwon ^d   Kim, Hyung Ryong ^b   Chae, Soo Wan ^a,c   Chae, Han Jung ^a  

^a Chonbuk National University   (South Korea)

^b Wonkwang University   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Gochang Black Raspberry Research Institute   (South Korea)

Author keywords

Apolipoprotein B; Cholesterol; HepG2; Rubus coreanus; Sterol regulatory element binding protein 1

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHOENOLPYRUVATE CARBOXYLASE; PLANT EXTRACT; RUBUS COREANUS EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ANTIHYPERLIPIDEMIC ACTIVITY; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DRUG ACTIVITY; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIPID METABOLISM; LIVER CELL; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; FATTY ACIDS; FORKHEAD TRANSCRIPTION FACTORS; GLUCOSE-6-PHOSPHATASE; HEP G2 CELLS; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; PLANT EXTRACTS; PROTEIN-SERINE-THREONINE KINASES; ROSACEAE; SOLVENTS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; WATER;

EID: 84869205179     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00022     Document Type: Article

References (31)

1. Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2mg/L). J. Clin. Lipidol., 5, 401-407 (2011).
2. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein. Atherosclerosis, 217, 492-498 (2011).
3. Brouwers MC, Stehouwer CD. Niacin in cardiovascular patients receiving statins. N. Engl. J. Med., 366, 1255-1256 (2012).
4. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation, 114, 2655-2662 (2006).
5. Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F, Cravotto G. Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol. Lipids, 44, 907-916 (2009).
6. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J. Am. Coll. Cardiol., 52, 626-632 (2008).
7. Lee SH, Cho KI, Kim JY, Ahn YK, Rha SW, Kim YJ, Choi YS, Choi SW, Jeon DW, Min PK, Choi DJ, Baek SH, Kim KS, Byun YS, Jang Y. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis, 221, 169-175 (2012).
8. Tomé-Carneiro J, Gonzálvez M, Larrosa M, García-Almagro FJ, Avilés-Plaza F, Parra S, Yáñez- Gascón MJ, Ruiz-Ros JA, García-Conesa MT, Tomás- Barberán FA, Espín JC. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res., 56, 810-821 (2012).
9. Ko SH, Choi SW, Ye SK, Yoo S, Kim HS, Chung MH. Comparison of anti-oxidant activities of seventy herbs that have been used in Korean traditional medicine. Nurs. Res. Pract., 2, 143-151 (2008).
10. Lim JW, Hwang HJ, Shin CS. Polyphenol compounds and anti-inflammatory activities of Korean black raspberry (Rubus coreanus MIQUEL) wines produced from juice supplemented with pulp and seed. J. Agric. Food Chem., 60, 5121-5127 (2012).
11. Lim JW, Jeong JT, Shin CS. Component analysis and sensory evaluation of Korean black raspberry (Rubus coreanus MIQUEL) wines. Int. J. Food Sci. Technol., 47, 918-926 (2012).
12. Choi J, Lee KT, Ha J, Yun SY, Ko CD, Jung HJ, Park HJ. Antinociceptive and antiinflammatory effects of Niga-ichigoside F1 and 23-hydroxytormentic acid obtained from Rubus coreanus. Biol. Pharm. Bull., 26, 1436-1441 (2003).
13. Nam JH, Jung HJ, Choi J, Lee KT, Park HJ. The anti-gastropathic and anti-rheumatic effect of niga-ichigoside F1 and 23-hydroxytormentic acid isolated from the unripe fruits of Rubus coreanus in a rat model. Biol. Pharm. Bull., 29, 967-970 (2006).
14. Lee KH, Choi EM. Rubus coreanus MIQUEL extract promotes osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells. Am. J. Chin. Med., 34, 643-654 (2006).
15. Lee JE, Park E, Lee JE, Auh JH, Choi HK, Lee J, Cho S, Kim JH. Effects of a Rubus coreanus MIQUEL supplement on plasma antioxidant capacity in healthy Korean men. Nurs. Res. Pract., 5, 429-434 (2011).
16. Ra JC, Kang KS, Lee HY, Choi MK, Park HG. Effect of decreasing body weight with plant extracts containing Rubu Fructus. J. Toxicol. Pub. Health, 20, 167-172 (2004).
17. Choi JW, Yoo YM, Kim MY, Nam JH, Nugroho A, Park HJ. Antihyperglycemic and anti-hyperlipidemic effects of the triterpenoid-rich fractions from Rubus coreanus and Rubus crataegifolius and their main components, Niga-ichigoside F1, in Streptozotocin-induced rats. Nat. Prod. Sci., 14, 260-264 (2008).
18. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J. Nutr., 131, 989S-993S (2001).
19. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, Ernie S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med. Indones., 40, 201-210 (2008).
20. Farnier M, Taggart W, Dong Q, Lin J, Shah A, Brudi P. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients. J. Clin. Lipidol., 5, 179-187 (2011).
21. Tada H, Kawashiri MA, Ikewaki K, Terao Y, Noguchi T, Nakanishi C, Tsuchida M, Takata M, Miwa K, Konno T, Hayashi K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ. Cardiovasc. Genet., 5, 35-41 (2012).
22. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ Jr. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J. Lipid Res., 44, 1887-1901 (2003).
23. Haeusler RA, Han S, Accili D. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J. Biol. Chem., 285, 26861-26868 (2010).
24. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev., 22, 169-188 (2004).
25. Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J. Lipid Res., 48, 2334-2343 (2007).
26. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 55, 2180-2191 (2006).
27. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. Regulation of fasted blood glucose by resistin. Science, 303, 1195-1198 (2004).
28. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans., 30, 1064-1070 (2002).
29. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol., 574, 63-71 (2006).
30. Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitzgen U, Muller-Wieland D, Kotzka J. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS ONE, 7, e31812 (2012).
31. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology, 141, 1393-1403 (2011).